{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:49:14Z","timestamp":1792111754152,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer burden in patients aged 85\u00a0years and older has rapidly increased accompanying the decrease in mortality, which is raising the concern of developing second primary malignant neoplasms (SPM). This study aimed to investigate the epidemiology of the SPM in this population in the US by using the surveillance, epidemiology, and end results database (1975\u20132016). The cumulative incidence of developing a SPM was calculated by the Fine and Gray model. Standardized incidence ratios (SIR) were calculated via Poisson regression. The relative post-SPM survival rate was calculated by the Kaplan\u2013Meier method. Male patients with skin melanoma, kidney and renal pelvis and urinary bladder cancers had high cumulative incidences (15.32%, 13.55%, and 12.26%, respectively) and increased SIRs (1.47, 1.44, and 1.16, respectively) for developing SPMs. Female patients with skin melanoma and urinary bladder cancers had high cumulative incidences (10.18% and 7.87%, respectively) and increased SIRs (1.34 and 1.18, respectively). In general, the incidence of SPM cases increased over time. The median latency ranged from 17 to 37\u00a0months. A less than 50% of patients had 1-year post-SPM survival. In conclusion, some of these patients had an increased risk of the SPM, with poor survival.<\/jats:p>","DOI":"10.1038\/s41598-022-15746-x","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T17:03:43Z","timestamp":1657299823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Epidemiological analysis of second primary malignant neoplasms in cancer survivors aged 85\u00a0years and older: a SEER data analysis (1975\u20132016)"],"prefix":"10.1038","volume":"12","author":[{"given":"Xianlan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"15746_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3322\/caac.21577","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis, C. E. et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J. Clin. 69, 452\u2013467. https:\/\/doi.org\/10.3322\/caac.21577 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"15746_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwaa236","author":"T Tanskanen","year":"2020","unstructured":"Tanskanen, T., Seppa, K. J. M., Virtanen, A., Malila, N. K. & Pitkaniemi, J. M. Cancer incidence and mortality in the oldest old: a nationwide study in Finland. Am. J. Epidemiol. https:\/\/doi.org\/10.1093\/aje\/kwaa236 (2020).","journal-title":"Am. J. Epidemiol."},{"key":"15746_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-16-0133","volume":"25","author":"SM Bluethmann","year":"2016","unstructured":"Bluethmann, S. M., Mariotto, A. B. & Rowland, J. H. Anticipating the \u201csilver tsunami\u201d: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol. Biomark. Prev. 25, 1029\u20131036. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-0133 (2016).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"15746_CR4","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1001\/jamaoncol.2017.0465","volume":"3","author":"THM Keegan","year":"2017","unstructured":"Keegan, T. H. M., Bleyer, A., Rosenberg, A. S., Li, Q. & Goldfarb, M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 3, 1554\u20131557. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0465 (2017).","journal-title":"JAMA Oncol."},{"key":"15746_CR5","doi-asserted-by":"publisher","first-page":"19748","DOI":"10.1038\/s41598-021-99260-6","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. Second primary malignancy among malignant solid tumor survivors aged 85 years and older. Sci. Rep. 11, 19748. https:\/\/doi.org\/10.1038\/s41598-021-99260-6 (2021).","journal-title":"Sci. Rep."},{"key":"15746_CR6","doi-asserted-by":"publisher","first-page":"638","DOI":"10.21037\/atm-20-2059","volume":"8","author":"X Zheng","year":"2020","unstructured":"Zheng, X. et al. Second primary malignancies among cancer patients. Ann. Transl. Med. 8, 638. https:\/\/doi.org\/10.21037\/atm-20-2059 (2020).","journal-title":"Ann. Transl. Med."},{"key":"15746_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/ijc.32101","volume":"145","author":"E Adjei Boakye","year":"2019","unstructured":"Adjei Boakye, E. et al. Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States. Int. J. Cancer 145, 143\u2013153. https:\/\/doi.org\/10.1002\/ijc.32101 (2019).","journal-title":"Int. J. Cancer"},{"key":"15746_CR8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s10147-019-01430-0","volume":"24","author":"JL Wei","year":"2019","unstructured":"Wei, J. L., Jiang, Y. Z. & Shao, Z. M. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int. J. Clin. Oncol. 24, 934\u2013940. https:\/\/doi.org\/10.1007\/s10147-019-01430-0 (2019).","journal-title":"Int. J. Clin. Oncol."},{"key":"15746_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s10120-015-0482-3","volume":"19","author":"SC Chen","year":"2016","unstructured":"Chen, S. C. et al. Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan. Gastric Cancer 19, 490\u2013497. https:\/\/doi.org\/10.1007\/s10120-015-0482-3 (2016).","journal-title":"Gastric Cancer"},{"key":"15746_CR10","first-page":"130","volume":"44","author":"B Miller","year":"2017","unstructured":"Miller, B., Feuer, E. & Altekruse, S. Cancer incidence patterns in the oldest ages using expanded age categories from SEER registry data and the 2010 census population. J. Registry Manag. 44, 130\u2013135 (2017).","journal-title":"J. Registry Manag."},{"key":"15746_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/MAJ.0000000000000281","volume":"348","author":"JP Thakkar","year":"2014","unstructured":"Thakkar, J. P., McCarthy, B. J. & Villano, J. L. Age-specific cancer incidence rates increase through the oldest age groups. Am. J. Med. Sci. 348, 65\u201370. https:\/\/doi.org\/10.1097\/MAJ.0000000000000281 (2014).","journal-title":"Am. J. Med. Sci."},{"key":"15746_CR12","doi-asserted-by":"publisher","first-page":"e2384","DOI":"10.7759\/cureus.2384","volume":"10","author":"JD Parekh","year":"2018","unstructured":"Parekh, J. D., Kukrety, S., Thandra, A. & Valenta, C. Multiple primary malignant neoplasms in an elderly patient. Cureus 10, e2384. https:\/\/doi.org\/10.7759\/cureus.2384 (2018).","journal-title":"Cureus"},{"key":"15746_CR13","doi-asserted-by":"publisher","first-page":"e000172","DOI":"10.1136\/esmoopen-2017-000172","volume":"2","author":"A Vogt","year":"2017","unstructured":"Vogt, A. et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open 2, e000172. https:\/\/doi.org\/10.1136\/esmoopen-2017-000172 (2017).","journal-title":"ESMO Open"},{"key":"15746_CR14","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards, B. K. et al. Annual Report to the Nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120, 1290\u20131314. https:\/\/doi.org\/10.1002\/cncr.28509 (2014).","journal-title":"Cancer"},{"key":"15746_CR15","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/bjc.2012.46","volume":"106","author":"TL Jorgensen","year":"2012","unstructured":"Jorgensen, T. L., Hallas, J., Friis, S. & Herrstedt, J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br. J. Cancer 106, 1353\u20131360. https:\/\/doi.org\/10.1038\/bjc.2012.46 (2012).","journal-title":"Br. J. Cancer"},{"key":"15746_CR16","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, Nov. 2018 Sub (1975\u20132016)<Katrina\/ Rita Population Adjustment>-Linked To County Attributes-Total US, 1969\u20132016 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch (2019)."},{"key":"15746_CR17","unstructured":"Johnson, C., Peace, S., Adamo, P., Fritz, A., Percy-Laurry, A. & Edwards, B. Multiple primary and histology coding rules manual in the national cancer institute, surveillance. Epidemiology and End Results Program (Revised Edition) 2016. (National Cancer Institute, 2014)."},{"key":"15746_CR18","unstructured":"https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2020\/TextData.FileDescription.pdf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15746-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:34:54Z","timestamp":1669358094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15746-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["15746"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-15746-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"9 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11688"}}